<DOC>
	<DOCNO>NCT02716220</DOCNO>
	<brief_summary>BIOSOLVE-III Study pre-market , prospective , multi-center trial ass acute clinical performance DREAMS 2G Drug-Eluting Coronary Scaffold de novo coronary artery lesion .</brief_summary>
	<brief_title>Pre-market Study DREAMS 2G Drug Eluting Absorbable Metal Scaffold ( BIOSOLVE-III )</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<criteria>1 . Subject &gt; 18 year &lt; 80 year age 2 . Written subject informed consent available prior PCI 3 . Subjects stable unstable angina pectoris document silent ischemia 4 . Subject eligible PCI 5 . Subject acceptable candidate coronary artery bypass surgery 6 . Subjects maximum two single lesion two separate coronary artery de novo lesion . 7 . Reference vessel diameter 2.73.8 mm visual estimation , depend scaffold size use . 8 . Target lesion length visual estimation , assist QCA : &lt; 21 mm , depend scaffold size use . 9 . Target lesion stenosis visual estimation , assist QCA &gt; 50 % &lt; 100 % 10 . Eligible Dual Anti Platelet Therapy ( DAPT ) 1 . Pregnant breastfeeding female females intend become pregnant time study 2 . Evidence myocardial infarction within 72 hour prior index procedure 3 . Subjects ≥2 fold CK level absence CK ≥3 fold CKMB level upper range limit within 24 hour prior procedure 4 . Left main coronary artery disease 5 . Threevessel coronary artery disease time procedure 6 . Thrombus target vessel 7 . Subject currently participate another study investigational device investigational drug reach primary endpoint yet 8 . Planned interventional treatment nontarget vessel within 30 day post procedure 9 . Subjects dialysis 10 . Planned intervention target vessel index procedure 11 . Ostial target lesion ( within 5.0 mm vessel origin ) 12 . Target lesion involves side branch &gt; 2.0 mm diameter 13 . Documented leave ventricular ejection fraction ( LVEF ) ≤ 30 % 14 . Heavily calcified lesion 15 . Target lesion locate supply arterial venous bypass graft 16 . The target lesion require treatment device predilatation balloon prior scaffold placement ( include limit directional coronary atherectomy , excimer laser , rotational atherectomy , etc . ) 17 . Unsuccessful predilatation , define minimal lumen diameter small respective crossing profile DREAMS 2G angiographic complication ( e.g . distal embolization , side branch closure , extensive dissection ca n't cover single scaffold ) , visual estimation 18 . Known allergy : Acetylsalicylic Acid ( ASA ) , Heparin , contrast medium , Sirolimus , Everolimus similar drug ( i.e. , ABT 578 , Biolimus , Tacrolimus ) , PLLA , Silicon Carbide Magnesium , Yttrium , Neodymium , Zirconium , Gadolinium , Dysprosium , Tantalum 19 . Impaired renal function ( serum creatinine &gt; 2.5 mg/dl 221mmol/l ) determine within 72 hour prior intervention 20 . Subject receive oral intravenous immunosuppressive therapy ( inhaled steroid exclude ) know lifelimiting immunosuppressive autoimmune disease ( e.g. , human immunodeficiency virus , systemic lupus erythematosus , include diabetes mellitus ) 21 . Proximal distal target lesion locate stenosis might require future revascularization impede run detect diagnostic angiography 22 . Life expectancy less 1 year , comorbidities ( e.g . Sepsis , Apoplexy TIA within 6 month prior study procedure ) ( Comorbidities definition leave discretion Study Investigators ) 23 . Planned surgery dental surgical procedure within 6 month index procedure 24 . Subject tortuous vessel may impair scaffold placement region obstruction proximal lesion 25 . In investigator opinion subject able comply followup Requirements</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>DREAMS 2G</keyword>
	<keyword>Scaffold</keyword>
	<keyword>Drug Eluting Absorbable Metal Scaffold</keyword>
	<keyword>Coronary Artery Disease</keyword>
</DOC>